GuidelinesOther guideline
Abbreviations
National Essential Medicines List Committee (NEMLC), June 2021
| Abbreviations | Name |
| ACTH | Adrenocorticotropic hormone |
| ARB | Angiotensin II receptor blocker |
| AR | Antiretroviral |
| ATAC | Arimidex, tamoxifen, alone or in combination |
| ATC | Anatomical Therapeutic Chemical Classification |
| BCG | Bacille Calmette-Guerin |
| Big 1-98 | Breast International Group 1-98 |
| COCs | Combined oral contraceptives |
| COPD | Chronic Obstructive Pulmonary Disease |
| DLBCL | Diffuse large B-cell non-Hodgkins lymphoma |
| DMARD | Disease-modifying antirheumatic drugs |
| DoH | Department of Health |
| EML | Essential Medicine List |
| ESRD | End-stage renal disease |
| FGAs | First generation antipsychotics |
| FL | Follicular lymphoma |
| GCSF | Granulocyte colony stimulating factor |
| GFR | Glomerular filtration rate |
| GnRH | Gonadotrophin-releasing hormones |
| HIV | Human Immunodeficiency Virus |
| HR-ALL | High-risk Acute Lymphoblastic Leukaemia |
| IPI | International Prognostic Index |
| ITP | Immune Thrombocytopenic Purpura |
| IVF | In-vitro Fertilisation |
| IVIG | Intravenous Immunoglobulin |
| LTRA | Leukotriene receptor antagonists |
| mBC | Metastatic breast cancer |
| MRSA | Methicillin-resistant Staphylococcus aureus |
| NPH | Neutral Protamine Hagedorn |
| PPI | Proton Pump Inhibitor |
| PTC | Pharmaceutical and Therapeutics Committee |
| RA | Rheumatoid arthritis |
| RCT | Randomised controlled trais |
| RSV | Respiratory syncytial virus |
| SEP | Single Exit Price |
| TEAM | Tamoxifen Exemestane Adjuvant Multinational |
| TNF | Tumour necrosis factor |
| VCZ | Voriconazole |
| VTD | Bortezomib/thalidomide/corticosteroids |
| VHF | Viral haemorrhhagic fever |
| WCC | White cell count |
Note:
General review indicators include, new evidence on efficacy, effectiveness or safety and significant price changes
| NEMLC ratified Summary and Review documents can be requested as required from: SAEDP@health.gov.za OR Jane.Riddin@health.gov.za |